Status:
COMPLETED
Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle
Lead Sponsor:
Becton, Dickinson and Company
Conditions:
Diabetes
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This is a subject single blinded, block randomized, prospective, single-visit, multi-center study to compare user experiences with BD Nano™ PRO pen needle vs. the thinner commercially available Terumo...
Detailed Description
Study conduct will consist of one 60 to 120-minute Site visit in which pre-set doses of saline will be abdominally delivered by Subjects via a reusable insulin pen device. All pen needles will be atta...
Eligibility Criteria
Inclusion
- Self-attesting Japanese American adults 18 to 75 years of age (inclusive).
- Self-attest to Japanese descent.
- Diagnosed with Type 1 or Type 2 diabetes.
- Self-injecting using an injection pen for ≥3 months with any pen needle.
- Injecting a minimum of ≥10 units of insulin and/or Victoza at least once per day.
- Able to demonstrate proficiency using an injection pen into an injection model.
- Able and willing to provide informed consent.
- Able and willing to complete all study procedures.
Exclusion
- Not self-injecting (for example injections completed by a family member).
- Self-injecting with a pen injector for less than 3 months.
- Unwilling to inject into abdomen.
- Unwilling to have hair at the injection area reduced with an electric razor if it is determined the hair will interfere with leakage evaluation.
- Failure to confirm which pen needle (gauge and needle length) subject is currently using. To confirm, subject may be asked to bring their pen and pen needles to the site or site staff may confirm via medical record or pharmacy.
- Pregnant (self-attestation).
- Currently taking anti-platelet or anticoagulant therapy (up to 162 mg per day of aspirin is permitted).
- History of a bleeding disorder.
- History of recurrent dermatological conditions or skin disorder (e.g., psoriasis, eczema).
- Gross skin anomalies and abnormalities located at or very close to the injection sites that would significantly limit available injection space.
- History of symptomatic low blood pressure or history of fainting (syncope) during hypodermic injections.
- Use of any analgesic medications within 24 hours of first study injection, and during the study (up to 162 mg per day of aspirin is permitted).
- A current or previous medical or physical condition that, in the opinion of the investigator, would place the patient at risk or make them unable to perform study procedures or has the potential to confound interpretation of the study results.
- Currently participating in another pen needle study.
- Employed by, or currently serving as a contractor or consultant to BD or any diabetes injectable medication, injection pen, or pen needle manufacturer.
Key Trial Info
Start Date :
February 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 14 2019
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT03878745
Start Date
February 11 2019
End Date
June 14 2019
Last Update
May 19 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mills-Peninsula Medical Center Dorothy L. and James E Frank Diabetes Research Institute
San Mateo, California, United States, 94401
2
East West Medical Research Institute
Honolulu, Hawaii, United States, 96814